| Identification | Back Directory | [Name]
GSK547 | [CAS]
2226735-55-1 | [Synonyms]
RIP1I GSK547 CPD3508 RIP1 inhibitor 547 RIP1 inhibitor GSK547 (S)-6-(4-(5-(3,5-Difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperidin-1-yl)pyrimidine-4-carbonitrile 4-Pyrimidinecarbonitrile, 6-[4-[[(5S)-5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl]carbonyl]-1-piperidinyl]- | [Molecular Formula]
C20H18F2N6O | [MDL Number]
MFCD32062767 | [MOL File]
2226735-55-1.mol | [Molecular Weight]
396.39 |
| Chemical Properties | Back Directory | [Boiling point ]
578.3±60.0 °C(Predicted) | [density ]
1.43±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:65.0(Max Conc. mg/mL);163.98(Max Conc. mM) | [form ]
Solid | [pka]
1.93±0.28(Predicted) | [color ]
White to off-white | [InChI]
InChI=1S/C20H18F2N6O/c21-15-7-14(8-16(22)9-15)18-1-4-26-28(18)20(29)13-2-5-27(6-3-13)19-10-17(11-23)24-12-25-19/h4,7-10,12-13,18H,1-3,5-6H2/t18-/m0/s1 | [InChIKey]
SJVGFKBLUYAEOK-SFHVURJKSA-N | [SMILES]
C1=NC(N2CCC(C(N3[C@H](C4=CC(F)=CC(F)=C4)CC=N3)=O)CC2)=CC(C#N)=N1 |
| Hazard Information | Back Directory | [Uses]
GSK547 (GSK'547) is a highly selective and potent inhibitor of receptor-interacting serine/threonine protein kinase 1 (RIPK1), inhibits macrophage-mediated adaptive immune tolerance in pancreatic cancer[1]. | [Biological Activity]
GSK'547 is a highly selective and potent inhibitor of RIP1 (RIPK1) with a 400-fold increase in oral exposure compared to GSK'963 in mouse pharmacokinetic studies. | [in vitro]
In vitro, treatment with GSK'547 directed bone marrow-derived macrophages to develop an immunogenic phenotype, with up-regulation of MHC-II, TNFa and IFNg expression, and decreased CD206, IL- 10 and TGFb expression. In addition, it also up-regulated STAT1 signaling and decreased STAT3, STAT5 and STAT6 signaling in bone marrow-derived macrophages. Macrophages treated with GSK'547 had stronger ability to capture antigens. | [in vivo]
Mice were given GSK'547 through food, the concentration of GSK'547 in vivo was stable within 24 hours, which was higher than the IC50 value in L929 cells. GSK'547 maintained high concentrations in vivo during the 6-week administration. GSK'547 was well tolerated with no obvious pathological features. In mice with in situ pancreatic ductal adenocarcinoma, It reduced tumor burden and prolonged survival compared to control and Nec-1s-treated groups. GSK'547 prevents established tumors and liver metastases. | [target]
| Target | Value | RIP1 () | table>[References]
[1] Wang W, et al. RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer. Cancer Cell. 2018 Nov 12;34(5):757-774.e7. DOI:10.1016/j.ccell.2018.10.006 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
|
|
Tags:2226735-55-1
Related Product Information
|
|
1627856-64-7
1346572-63-1
1652591-81-5
1346547-00-9
1010411-21-8
929095-18-1
1628332-52-4
1622849-58-4
1616392-22-3
188591-46-0
1362154-70-8
|
太仓市|
江孜县|
临潭县|
安义县|
八宿县|
明星|
西平县|
永川市|
中阳县|
乡宁县|
阳新县|
布尔津县|
桦川县|
延津县|
昭苏县|
广东省|
翁源县|
五大连池市|
崇左市|
图木舒克市|
拜城县|
安顺市|
西充县|
威海市|
桂东县|
扶风县|
崇仁县|
合作市|
梅河口市|
巴彦淖尔市|
丹棱县|
石棉县|
乐至县|
澄迈县|
息烽县|
瓦房店市|
乌兰浩特市|
沁水县|
利津县|
宁阳县|
永寿县|
|